At the core of this theranostic platform lies a sophisticated design that integrates AIE luminogens, materials known for their remarkable fluorescence properties that intensify upon aggregation, with radionuclide labels that emit signals detectable by advanced imaging modalities. Unlike traditional fluorophores, which often suffer from aggregation-caused quenching, AIE luminogens maintain or enhance their emission efficiency in the aggregated state, enabling deeper tissue penetration and clearer imaging within the NIR-II window (1000–1700 nm). This spectral region is particularly prized for its low tissue autofluorescence and reduced light scattering, dramatically improving image resolution and sensitivity for real-time tumor visualization.

The strategic conjugation of radionuclides to these NIR-II AIE luminogens not only augments the imaging capabilities but also introduces a therapeutic dimension. Radionuclide labeling enables the delivery of targeted radiotherapy, leveraging the emission of ionizing radiation to induce lethal DNA damage selectively within the malignant cells. This dual-functionality allows for a seamless transition from diagnosis to therapy—commonly referred to as theranostics—empowering clinicians with the ability to monitor therapeutic efficacy dynamically and adjust treatment protocols with precision. Such an approach promises to mitigate the systemic toxicity and side effects typically associated with conventional chemotherapy and radiotherapy.

Engineering this nanoplatform involved meticulous optimization of the physicochemical properties to ensure biocompatibility, stability, and favorable pharmacokinetics. The researchers employed a robust synthetic route that stabilized the luminogens within a biocompatible matrix, facilitating prolonged circulation times, preferential tumor accumulation via the enhanced permeability and retention (EPR) effect, and efficient cellular uptake. Surface modifications further endowed the nanoparticles with active targeting ligands, enhancing specificity towards tumor-associated receptors, reducing off-target interactions, and improving therapeutic indices.

Beyond its molecular design, the theranostic nanoplatform was evaluated through an array of preclinical models, exhibiting remarkable tumor delineation capabilities when subjected to high-resolution NIR-II fluorescence imaging. The system allowed for early, precise tumor margin identification, an essential factor in surgical oncology to ensure complete resection and minimize recurrence. Complementarily, radionuclide imaging facilitated noninvasive whole-body scanning, helping to detect metastatic lesions that conventional imaging techniques might overlook.

The therapeutic capabilities were rigorously tested, demonstrating dose-dependent cytotoxic effects on cancer cells with minimal impact on surrounding healthy tissues. The integration of controlled radionuclide decay kinetics enabled the modulation of therapeutic payload release, achieving a potent but localized radiation impact. This precision markedly enhances the therapeutic window and significantly diminishes collateral damage, a longstanding challenge in the treatment of resistant or inoperable malignancies.

One of the most impressive aspects of this platform is its adaptability. The modular nature of the nanoplatform allows the incorporation of various radionuclides, tailored to specific diagnostic or therapeutic needs. For instance, short-lived isotopes can be utilized for rapid imaging, while longer-lived radionuclides provide sustained therapeutic effects. This adaptability paves the way for personalized oncology, where treatments are fine-tuned based on individual tumor biology and patient metabolism.

Furthermore, the platform’s design overcomes several limitations of current imaging and therapeutic methods, including poor tissue penetration, photobleaching, and nonspecific distribution. By exploiting the NIR-II window and harnessing AIE luminogens’ robust optical performance, the system offers greater imaging depth with higher signal-to-noise ratios. Concurrently, radionuclide therapeutic agents circumvent multidrug resistance pathways common in chemotherapy, potentially benefiting patients with refractory cancers.

The safety profile was a focal point in the development process. Comprehensive toxicity assays performed in vivo demonstrated minimal immunogenicity and negligible systemic toxicity, even at therapeutic doses. The nanoparticles were metabolized and cleared efficiently, emphasizing their suitability for clinical translation. Importantly, the reproducibility and scalability of the synthesis process were validated, addressing key manufacturing considerations critical for regulatory approval and widespread adoption.

This breakthrough signifies a pivotal moment in precision cancer care, harmonizing diagnostic precision, therapeutic efficacy, and personalized treatment planning in a single nanoformulation. The ability to visualize tumors with unmatched clarity and simultaneously deliver focused radionuclide therapy could radically improve patient outcomes, reduce treatment durations, and alleviate the debilitating side effects associated with current standards of care.

As the field moves towards clinical trials, the implications of this integrative nanoplatform extend beyond oncology. Its foundational principles may be adapted for managing other complex diseases requiring targeted imaging and treatment, such as cardiovascular pathologies and neurodegenerative disorders. The convergence of nanotechnology, nuclear medicine, and photophysics heralds a new era where multifunctional nanoprobes are key players in precision medicine.

Collaborators emphasize that while additional studies are warranted to optimize dosing regimens, biodistribution, and long-term effects, the current data robustly support the nanoplatform’s potential as a transformative tool in cancer therapy. Future work will likely focus on combining this approach with emerging immunotherapies and gene editing techniques, potentially orchestrating multifaceted assaults on tumors resistant to existing modalities.

In summary, this integrated nanoplatform exemplifies the union of innovation and practicality, offering a versatile, clinically relevant solution to the longstanding challenges in oncology. By unlocking the capabilities of radionuclide-labeled NIR-II AIE luminogens, researchers have paved a path toward more precise, effective, and patient-friendly cancer diagnosis and therapy. Such advancements underscore the vital role of interdisciplinary collaboration in tackling complex diseases and hold promise for elevating standards of care worldwide.

Subject of Research: Development of a multifunctional nanoplatform combining radionuclide-labeled NIR-II aggregation-induced emission luminogens for integrated cancer diagnosis and therapy.

Article Title: Integrated theranostic nanoplatform empowers precision cancer care via radionuclide-labeled NIR-II aggregation-induced emission luminogens.

Article References: Zhang, GL., Hou, DY., Chen, Y. et al. Integrated theranostic nanoplatform empowers precision cancer care via radionuclide-labeled NIR-II aggregation-induced emission luminogens. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74359-4

Image Credits: AI Generated

The LiBIO score utilizes a blood-based liquid biopsy technique, a non-invasive approach gaining momentum for its ability to provide dynamic insights into the molecular and immune landscape of cancer patients. The model specifically predicts patient responsiveness to immune checkpoint blockade (ICB) drugs, a class of immunotherapies that have shown remarkable success by unleashing the immune system’s ability to target and destroy tumor cells. By assessing circulating immune cells through serial liquid biopsies, the LiBIO approach offers a real-time window into the evolving cancer-immunity interplay, allowing clinicians to intervene promptly and tailor treatments for optimal outcomes.

Dr. Kun Wang, assistant professor of comparative biosciences and bioengineering, highlights the significance of this advancement. Head and neck squamous cell carcinoma (HNSCC), the focus of this study, often exhibits variable responses to immunotherapy, complicating treatment strategies. “Current clinical practice lacks reliable, minimally invasive biomarkers capable of predicting which patients will derive benefit from ICB therapies,” Wang explains. The LiBIO score fills this critical gap by enabling precise early identification of responders, sparing non-responders from unnecessary treatment-related toxicity and enabling more efficient resource allocation.

Underlying the LiBIO score is a detailed analysis of immune cell populations within peripheral blood samples taken before and after ICB administration. Leveraging a mouse model of HNSCC, the researchers conducted longitudinal monitoring to capture immune dynamics over time. Intriguingly, they identified that an early post-treatment increase in specific subsets of ‘cancer-fighting’ immune cells—namely, effector memory T cells and B cells—correlated strongly with positive therapeutic outcomes. Effector memory T cells are known for their rapid response to tumor antigens, while B cells contribute through antibody production and antigen presentation, suggesting a synergistic immune response to the tumor microenvironment induced by ICB therapy.

The temporal aspect of monitoring was critical in demarcating effective immune activation. Recognizing and validating an optimal early time point post-therapy initiation allowed the scientists to pinpoint a gene expression signature tied to the relevant immune cellular subsets. This gene signature forms the molecular basis of the LiBIO score, serving as a surrogate biomarker that captures the immune system’s readiness to mount an effective anti-tumor attack. This approach contrasts with previous static or invasive tumor biopsies, which fail to dynamically reflect evolving immune responses during treatment.

The predictive accuracy of the LiBIO model surpasses that of existing biomarkers, which often rely on tumor mutational burden or PD-L1 expression levels and yield inconsistent predictive power. Impressively, the LiBIO score demonstrates broad applicability beyond HNSCC, showing promise in predicting immunotherapy responses in malignancies such as breast cancer, lung cancer, and melanoma. This generalizability underscores the pivotal role of systemic immune parameters over tumor-intrinsic factors alone, expanding the clinical utility across diverse cancer types.

The clinical implications of adopting the LiBIO score are profound. By stratifying patients according to their likelihood of benefiting from ICB therapies, clinicians can personalize treatment regimens, reducing exposure to ineffective therapies and associated adverse effects. Moreover, the blood-based nature of this test allows for frequent, minimally invasive monitoring of patients’ immune status during therapy, facilitating dynamic treatment adjustments. Dr. Wang emphasizes, “This tool not only improves therapeutic precision but also empowers clinicians with molecular-level insights during the critical phases of immunotherapy.”

Buoyed by these promising preclinical results, the research team is actively seeking to translate the LiBIO score into clinical trials involving human patients. Dr. Robert Saddawi-Konefka, a key collaborator and physician-scientist at MD Anderson Cancer Center, is spearheading efforts to design and propose trials aimed at validating the biomarker’s predictive power in diverse clinical settings. Although timelines for initiation remain tentative, the groundwork laid by this multi-institutional collaboration instills confidence that human application is imminent.

Future studies will delve deeper into the mechanistic underpinnings of the immune interactions captured by the LiBIO score. While it is established that both effector memory T cells and B cells contribute to enhanced immunotherapy responses, the molecular and cellular crosstalk that potentiates this synergy remains elusive. The research team aims to unravel the precise pathways through which B cells augment T cell-mediated anti-tumor activity. Insights gained may enable the design of next-generation combination immunotherapies that deliberately enhance this interaction to amplify treatment efficacy and overcome resistance.

This pioneering work also raises intriguing questions about the dynamic immune landscape during cancer treatment. The deployment of liquid biopsies to assess immune repertoire diversity—through T cell receptor (TCR) and B cell receptor (BCR) analyses—provides a window into adaptive immune evolution under therapeutic pressure. Understanding how these repertoires shift in responders versus non-responders may identify novel therapeutic targets or resistance mechanisms, heralding a paradigm shift in immunotherapy monitoring.

As the field of cancer immunotherapy advances, tools like the LiBIO score exemplify the fusion of cutting-edge molecular profiling with clinical oncology. By integrating immune biomarkers into treatment algorithms, oncology is moving towards highly personalized interventions that optimize patient outcomes while minimizing unnecessary toxicity. This approach aligns with the broader vision of precision medicine, where dynamic patient-specific data guides not only therapy selection but also real-time adjustments.

In summary, the development of the LiBIO score represents a critical stride in overcoming one of immunotherapy’s major hurdles—the variability in patient response. By exploiting a combination of blood-based immune profiling and longitudinal tracking, this biomarker facilitates early and accurate prediction of treatment success. Its impending clinical translation could revolutionize immunotherapy protocols across multiple cancer types, making treatments safer, more effective, and more accessible. This advancement embodies the promise of translational research to deliver tangible benefits to patients battling cancer worldwide.

Subject of Research:
Immune biomarker development and predictive modeling for immunotherapy response in head and neck squamous cell carcinoma through longitudinal liquid biopsies.

Article Title:
Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma

News Publication Date:
1-Sep-2025

Web References:
https://www.nature.com/articles/s41467-025-63538-4

References:
Wang, K. et al. Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma. Nature Communications (2025). DOI: 10.1038/s41467-025-63538-4

Keywords:
Head and neck cancer, immune checkpoint blockade, immunotherapy, liquid biopsy, effector memory T cells, B cells, predictive biomarker, cancer immunotherapy, immune monitoring, precision oncology

The core innovation lies in the development and application of SnOx nanoflakes synthesized through the electrochemical oxidation of tin disulfide (SnS2) powders. These two-dimensional nanostructures possess exceptional photothermal conversion capabilities, meaning they efficiently absorb near-infrared light and convert it into localized heat. When exposed to LED-generated near-infrared illumination, these nanoflakes become activated, generating enough thermal energy to induce targeted cancer cell death without harming nearby healthy cells. This selectivity is crucial in minimizing collateral damage, a pervasive issue in many current cancer treatments.

Traditional photothermal therapy typically relies on laser sources to direct intense light toward cancerous areas. While effective, lasers are expensive, require specialized and often immobile equipment, and risk damaging surrounding healthy tissues due to their high energy intensity. The substitution of lasers with LEDs in this new approach addresses these limitations directly. LEDs are widely available, cheaper, and can be engineered into compact, portable devices. This transition could democratize access to advanced cancer treatment technologies, especially in underserved regions where hospital-based specialized equipment is scarce.

In vitro experiments have produced compelling evidence supporting the efficacy and safety of this combined LED and SnOx nanoflake therapy. When cultured skin and colorectal cancer cells were exposed to near-infrared LED light in the presence of these nanoflakes, the system achieved up to 92% destruction of skin cancer cells and 50% eradication of colorectal cancer cells within just 30 minutes of treatment. Crucially, these results were obtained without observable detrimental effects on healthy human skin cells, highlighting the treatment’s precision and biocompatibility.

This technology harnesses the principles of near-infrared photothermal therapy, which exploits the tissue-penetrative properties of near-infrared light to deliver heat specifically to malignant cells. As these cancer cells absorb the light-activated heat produced by the SnOx nanoflakes, their local temperature rises to levels sufficient to induce apoptosis or necrosis. Because the therapy operates at relatively low light intensities and employs a biocompatible nanoparticle agent, it promises a gentler alternative to invasive surgical procedures or the systemic toxicity that accompanies many chemotherapeutic regimens.

The successful collaboration between researchers at UT Austin and the University of Porto is bolstered by the UT Austin Portugal Program, a long-standing bilateral scientific partnership bridging U.S. and Portuguese institutions. This program facilitated the transatlantic exchange of expertise, resources, and ideas that enabled the convergence of electrical engineering, materials science, and biomedical research inherent in this project. The synergistic efforts have yielded not only mechanistic insights but also practical prototypes, including custom-designed, near-infrared LED heating systems tailored to activate the SnOx nanoflakes efficiently.

Looking forward, the research team has set ambitious objectives to deepen understanding of the photothermal and photonic interactions governing the therapy’s effectiveness. Further investigation will explore alternative catalytic nanomaterial candidates that may offer enhanced efficacy or novel functional properties. Additionally, device engineering is a critical next step, focusing on developing user-friendly, portable platforms capable of delivering this therapy in clinical and even home-based settings, particularly for skin cancer patients.

One envisioned application is a wearable, lightweight device that a patient could place directly on the skin post-surgery to irradiate the surgical site and eradicate residual cancerous cells. Such an approach could significantly reduce recurrence rates and alleviate patients from repeated hospital visits. Moreover, the anticipated low-cost nature of the technology could facilitate adoption in low-resource environments worldwide, addressing long-standing disparities in cancer treatment accessibility.

The therapeutic use of SnOx nanoflakes also exemplifies the frontier of two-dimensional material science in biomedical applications. The nanoscale morphology and high surface area of these flakes enhance their interaction with near-infrared light and maximize thermal conversion. This precision targeting at the cellular level optimizes therapeutic outcomes while minimizing systemic side effects. The team continues to optimize the synthesis and functionalization of these nanomaterials, tailoring their physicochemical properties to improve stability, biocompatibility, and treatment efficacy.

An additional exciting outcome of this multidisciplinary venture is the recent procurement of supplementary funding aimed at developing an implantable device for breast cancer patients. This implant would integrate the photothermal capabilities of SnOx nanoflakes with minimally invasive delivery methods, representing an advanced step in personalized cancer therapy. It underscores the broad potential of this research beyond topical or external applications, opening avenues for treatment of diverse cancer types.

Besides the principal investigators, the research effort encompasses a diverse team of scientists and engineers. Their collective expertise spans electrical engineering, nanomaterial synthesis, biological characterization, and device engineering, epitomizing a modern collaborative approach to translational research. Notably, the development of the LED systems was spearheaded by contributors from the University of Trás-os-Montes and Alto Douro, showcasing a wide-reaching network of academic partnerships within Portugal.

This novel therapeutic approach is a landmark in photothermal cancer therapies, promising to surmount critical barriers hampering previous iterations of the technology. By leveraging more affordable and accessible LED technology alongside advanced nanomaterials, the method holds promise not only for improving patient outcomes but also for fundamentally reshaping cancer treatment modalities worldwide. Its evolution from laboratory discovery through clinical device development may transform how cancer is managed globally, combining cutting-edge science with practical healthcare delivery.

The fusion of material science, optical engineering, and oncology demonstrated in this work exemplifies the forward trajectory of cancer research. As this method progresses towards clinical trials and broader implementation, the scientific and medical communities will be closely watching its impact. With continued innovation, this LED-activated SnOx nanoflake therapy could inaugurate a new era of cancer treatment—one defined by precision, safety, accessibility, and hope for millions of patients worldwide.

Subject of Research: Cancer treatment using near-infrared photothermal therapy with SnOx nanoflakes activated by LED light.

Article Title: SnOx Nanoflakes as Enhanced Near-Infrared Photothermal Therapy Agents Synthesized from Electrochemically Oxidized SnS2 Powders

Web References:
https://doi.org/10.1021/acsnano.5c03135

References: ACS Nano, peer-reviewed journal article reporting experimental results and material synthesis details.

Image Credits: The University of Texas at Austin

Keywords: cancer, skin cancer, colorectal cancer, cancer cells, cancer research, cancer treatments

Magnetic hyperthermia therapy operates on a relatively straightforward physical principle: magnetic nanoparticles, once delivered and localized within a tumor mass, are subjected to an alternating magnetic field (AMF). This interaction induces localized heating, elevating the tumor temperature to between 41 and 46 degrees Celsius, the range known to sensitize cancer cells and trigger apoptosis without compromising surrounding healthy tissue. This degree of thermal elevation disrupts cellular homeostasis, destabilizes protein function, and impairs DNA repair mechanisms, thus amplifying the cytotoxic effects either directly or synergistically alongside chemotherapy and radiotherapy. The meticulous control of heat generation, now achievable through advances in nanoparticle engineering and AMF modulation, underscores the clinical promise of this approach.

The foundational components of MHT are magnetic nanoparticles, often engineered from biocompatible iron oxide variants such as magnetite (Fe3O4) or maghemite (γ-Fe2O3). These nanoscale entities exhibit superparamagnetic properties, enabling a rapid response to the applied magnetic field and efficient heat conversion through mechanisms including Néel and Brownian relaxation losses. Innovations in nanoparticle synthesis have refined particle size distribution, surface coating, and magnetic responsiveness to optimize therapeutic efficacy while minimizing toxicity and immunogenicity. Surface functionalization, employing polymers, antibodies, or ligands, allows for targeted delivery enhancing the preferential accumulation of nanoparticles within tumor microenvironments, thus sparing normal tissues and maximizing therapeutic windows.

One of the pivotal breakthroughs emerging from recent studies is the enhanced tumor specificity achieved through active targeting methods. By engineering magnetic nanoparticles to recognize and bind overexpressed biomarkers or receptors unique to cancer cells — such as folate receptors or HER2 — research teams have significantly improved intratumoral retention. This targeting capability not only optimizes therapeutic outcomes but also reduces off-target accumulation in organs like the liver and spleen, notoriously involved in nanoparticle clearance. Such precision in delivery is a leap forward, addressing prior limitations where nonspecific distribution hindered clinical translation of MHT.

Thermal dose control remains an intricate yet critical facet of magnetic hyperthermia’s clinical application. Advances in real-time temperature monitoring techniques, including magnetic resonance thermometry and infrared thermal imaging, allow clinicians to tailor AMF parameters dynamically. By modulating frequency, field strength, and exposure time, it is possible to achieve uniform tumor heating without overheating sensitive surrounding tissues. This precision mitigates adverse effects such as burns or inflammation, reinforcing MHT’s reputation as a minimally invasive yet potent therapeutic strategy.

Beyond standalone therapy, the synergistic potential of MHT with established cancer treatments has garnered substantial attention. Hyperthermia is known to sensitize tumor cells to radiation by increasing oxygenation and disrupting DNA repair pathways, rendering radiotherapy markedly more effective. Similarly, heat-induced vascular permeability alterations can enhance chemotherapeutic drug delivery into the tumor interstitium. Clinical trials exploring combined regimens report improved outcomes, lending strong clinical credence to integrated multipronged therapeutic strategies encompassing MHT.

Emerging paradigms employing multifunctional nanoparticle platforms are pushing the boundaries of treatment modalities further. These “theranostic” systems integrate therapeutic functionalities with diagnostic imaging capabilities, enabling simultaneous tumor visualization, treatment monitoring, and hyperthermic ablation. Magnetic nanoparticles conjugated with fluorescent probes or contrast agents facilitate MRI-guided hyperthermia, offering unparalleled treatment precision and immediate feedback on therapeutic progress. Such platforms embody the future of personalized medicine, built on the convergence of nanotechnology, imaging, and oncology.

Despite these promising developments, several critical challenges persist. One major hurdle is the heterogeneity of tumor microenvironments, which can influence nanoparticle penetration, distribution, and heating uniformity. Dense stromal matrices, variable vascularization, and elevated interstitial pressures may impede efficient nanoparticle delivery. Addressing these issues requires an improved understanding of tumor biology and the development of nanoparticle formulations tailored to overcome such physical barriers, perhaps through stimuli-responsive or matrix-degrading elements.

The safety profile and long-term biodistribution of magnetic nanoparticles remain paramount concerns on the path toward regulatory approval and mainstream clinical application. Although iron oxide-based nanoparticles have demonstrated generally favorable biocompatibility and biodegradability, systematic evaluations of cumulative toxicity, immunogenic responses, and potential alterations in cellular metabolism are ongoing. Future work will need to focus not only on acute safety but also on chronic effects, ensuring that therapeutic benefits decisively outweigh risks for patients.

Economics and scalability also mark important frontiers for magnetic hyperthermia. The complexity of nanoparticle synthesis, standardization of AMF delivery devices, and the necessity for sophisticated imaging and monitoring infrastructure impose challenges on widespread clinical implementation. Collaborative efforts between industry, academia, and healthcare institutions will be crucial to surmounting these barriers, enabling equitable access to MHT technologies across diverse healthcare settings.

Importantly, the rise of artificial intelligence and machine learning tools is poised to expedite innovation in MHT. Predictive modeling could optimize nanoparticle design, personalize dosing regimens, and predict patient-specific responses with unprecedented accuracy. Algorithms analyzing large datasets from preclinical and clinical studies will facilitate the rapid prototyping of next-generation therapeutic agents, accelerating bench-to-bedside transitions.

Patient-centric considerations further underscore the transformative impact of magnetic hyperthermia. With its minimally invasive nature, reduced systemic toxicity, and potential for outpatient delivery, MHT aligns with the growing demands for quality of life preservation alongside effective cancer control. Moreover, the adaptability of magnetic nanoparticle platforms to diverse tumor types—from solid malignancies like glioblastoma and pancreatic cancer to metastatic lesions—enriches its clinical versatility, positioning MHT as a universally applicable therapeutic adjunct.

As magnetic hyperthermia steadily advances through preclinical validation and early-phase clinical trials, integration with immunotherapy represents a tantalizing horizon. Heat generated by MHT can stimulate immunogenic cell death, releasing tumor antigens and potentiating immune responses. Coupling this effect with immune checkpoint inhibitors or cancer vaccines could synergize to orchestrate durable anti-tumor immunity, leading to long-lasting remission and functional cures.

In conclusion, the domain of magnetic hyperthermia therapy embodies a convergence of physics, materials science, and oncology, culminating in a sophisticated modality poised to redefine cancer treatment paradigms. While significant technical and biological challenges remain, ongoing multidisciplinary research highlights remarkable strides in nanoparticle design, targeting accuracy, thermal control, and combinatorial treatment approaches. This vibrant field promises not only to augment existing therapies but also to inaugurate wholly novel strategies that will ultimately improve survival and quality of life for cancer patients worldwide.

Subject of Research: Magnetic hyperthermia-based therapies for targeted cancer treatment.

Article Title: Magnetic hyperthermia-based therapies for cancer targeting: current progress and future perspectives.

Article References:
Rana, P., Garima, Devi, S. et al. Magnetic hyperthermia-based therapies for cancer targeting: current progress and future perspectives. Med Oncol 42, 453 (2025). https://doi.org/10.1007/s12032-025-03020-9

Image Credits: AI Generated